Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.

MLA

Akache, Bassel, et al. “Immunogenic and Efficacious SARS-CoV-2 Vaccine Based on Resistin-Trimerized Spike Antigen SmT1 and SLA Archaeosome Adjuvant.” Scientific Reports, vol. 11, no. 1, Nov. 2021, p. 21849. EBSCOhost, https://doi.org/10.1038/s41598-021-01363-7.

APA

Akache, B., Renner, T. M., Tran, A., Deschatelets, L., Dudani, R., Harrison, B. A., Duque, D., Haukenfrers, J., Rossotti, M. A., Gaudreault, F., Hemraz, U. D., Lam, E., Régnier, S., Chen, W., Gervais, C., Stuible, M., Krishnan, L., Durocher, Y., & McCluskie, M. J. (2021). Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. Scientific Reports, 11(1), 21849. https://doi.org/10.1038/s41598-021-01363-7

Chicago

Akache, Bassel, Tyler M Renner, Anh Tran, Lise Deschatelets, Renu Dudani, Blair A Harrison, Diana Duque, et al. 2021. “Immunogenic and Efficacious SARS-CoV-2 Vaccine Based on Resistin-Trimerized Spike Antigen SmT1 and SLA Archaeosome Adjuvant.” Scientific Reports 11 (1): 21849. doi:10.1038/s41598-021-01363-7.